The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic- pharmacodynamic modeling

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 7, 2010, Pages 396-406

  Ohno, Tomoya ^a   Hasegawa, Chihiro ^a   Nakade, Susumu ^a   Kitagawa, Junsaku ^a   Honda, Naoki ^a   Ogawa, Mikio ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

multiple sclerosis; pharmacodynamic; pharmacokinetic; sphingosine 1 phosphate; translational drug research

Indexed keywords

ONO 4641; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LYMPHOCYTE COUNT; MALE; MONKEY; NONHUMAN;

ANIMALS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MACACA FASCICULARIS; MICROSOMES, LIVER; PROTEIN BINDING; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 78649515645     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.719     Document Type: Article

References (29)

1. Martin R, McFarland HF, McFarlin DE,. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-187.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG,. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
3. Compston A, Coles A,. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
4. Sospedra M, Martin R,. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
5. Mandala S, Hajdu R, Bergstrom J, et al,. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
6. Kihara A, Mitsutake S, Mizutani Y, Igarashi Y,. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res 2007; 46: 126-144.
7. Sanna MG, Liao J, Jo E, et al,. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279: 13839-13848.
8. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG,. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005; 309: 1735-1739.
9. Massberg S, von Andrian UH,. Fingolimod and sphingosine-phosphate- modifiers of lymphocyte migration. N Engl J Med 2006; 355: 1088-1091.
10. Kappos L, Antel J, Comi G, et al,. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
11. Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA,. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008; 29: 186-191.
12. Meno-Tetang GM, Lowe PJ,. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005; 96: 182-192.
13. Beal SL, Sheiner LB,. NONMEM User's Guide. NONMEM Project Group, University of California at San Francisco: San Francisco, 1999.
14. Akaike H,. A new look at the statistical model identification. IEEE Trans Automat Control 1974; AC-19: 716-723.
15. Dayneka NL, Grag V, Jusko WJ,. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-478.
16. Pang KS, Rowland M,. Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model: Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625-653.
17. Boxenbaum H,. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980; 8: 165-176.
18. Sawada Y, Hanano M, Sugiyama Y, Harashima H, Iga T,. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J Pharmacokinet Biopharm 1984; 12: 587-596.
19. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA,. Methotrexate pharmacokinetics. J Pharm Sci 1971; 60: 1128-1133.
20. Slayter KL, Ludwig EA, Lew KH, Middleton E, Ferry JJ, Jusko WJ,. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1996; 59: 312-321.
21. Wald JA, Law RM, Ludwig EA, Sloan RR, Middleton E, Jusko WJ,. Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J Pharmacokin Biopharm 1992; 20: 567-589.
22. Wald JA, Salazar DE, Chen HY, Jusko WJ,. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmaco Exp Ther 1991; 301: 519-526.
23. Mullmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H,. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res 1995; 12: 1096-1110.
24. Magee MH, Blum RA, Lates CD, Jusko WJ,. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol 2002; 53: 474-484.
25. Stark JG, Werner S, Homrighausen S, et al,. Pharmacokinetic/ pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J Pharmacokinet Pharmacodyn 2006; 30: 598-607.
26. Rohatagi S, Zahir H, Moberly JB, et al,. Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator. J Clin Pharmacol 2009; 49: 50-62.
27. Fisher LE, Ludwig EA, Jusko WJ,. Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm 1992; 20: 319-331.
28. Piekoszewski W, Chow FS, Jusko WJ,. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. J Pharmacol Exp Ther 1994; 269: 103-109.
29. Palm S, Postler E, Hinrichsen H, Maier H, Zabel P, Kirch W,. Twenty-four-hour analysis of lymphocyte subpopulations and cytokines in healthy subjects. Chronobiol Int 1996; 13: 423-434.